JP Morgan Chase’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.63B Sell
20,820,621
-13,171,789
-39% -$1.74B 0.15% 140
2026
Q1
$4.63B Buy
33,992,410
+10,956,647
+48% +$1.53B 0.3% 69
2025
Q4
$2.83B Buy
23,035,763
+1,871,128
+9% +$227M 0.18% 119
2025
Q3
$2.35B Buy
21,164,635
+2,085,044
+11% +$237M 0.14% 149
2025
Q2
$2.12B Buy
19,079,591
+7,999,385
+72% +$851M 0.14% 146
2025
Q1
$1.24B Buy
11,080,206
+5,470,737
+98% +$564M 0.09% 212
2024
Q4
$518M Sell
5,609,469
-1,054,555
-16% -$95M 0.04% 374
2024
Q3
$559M Sell
6,664,024
-363,665
-5% -$27.7M 0.04% 360
2024
Q2
$482M Buy
7,027,689
+413,294
+6% +$27.6M 0.04% 378
2024
Q1
$485M Buy
6,614,395
+1,012,015
+18% +$77.8M 0.04% 390
2023
Q4
$454M Buy
5,602,380
+147,034
+3% +$11.4M 0.04% 379
2023
Q3
$409M Buy
5,455,346
+911,308
+20% +$70.1M 0.05% 356
2023
Q2
$350M Buy
4,544,038
+62,515
+1% +$4.99M 0.04% 403
2023
Q1
$372M Sell
4,481,523
-419,126
-9% -$34.7M 0.05% 368
2022
Q4
$421M Sell
4,900,649
-129,381
-3% -$10.2M 0.06% 325
2022
Q3
$310M Sell
5,030,030
-302,470
-6% -$19.1M 0.04% 375
2022
Q2
$330M Sell
5,332,500
-358,190
-6% -$22.2M 0.05% 370
2022
Q1
$338M Buy
5,690,690
+2,524,557
+80% +$161M 0.04% 405
2021
Q4
$230M Buy
3,166,133
+792,003
+33% +$54.6M 0.03% 525
2021
Q3
$166M Sell
2,374,130
-1,102,936
-32% -$77.5M 0.02% 633
2021
Q2
$239M Sell
3,477,066
-118,258
-3% -$7.9M 0.03% 546
2021
Q1
$232M Sell
3,595,324
-85,479
-2% -$5.51M 0.03% 526
2020
Q4
$214M Buy
3,680,803
+912,216
+33% +$55M 0.03% 507
2020
Q3
$172M Sell
2,768,587
-5,061
-0.2% -$351K 0.03% 521
2020
Q2
$213M Sell
2,773,648
-4,322,198
-61% -$331M 0.04% 422
2020
Q1
$530M Buy
7,095,846
+843,436
+13% +$58.3M 0.12% 175
2019
Q4
$406M Sell
6,252,410
-714,261
-10% -$46.5M 0.08% 272
2019
Q3
$442M Sell
6,966,671
-1,272,831
-15% -$83.2M 0.09% 253
2019
Q2
$553M Sell
8,239,502
-3,283,372
-28% -$216M 0.11% 199
2019
Q1
$749M Sell
11,522,874
-2,386,390
-17% -$159M 0.15% 143
2018
Q4
$870M Sell
13,909,264
-2,250,117
-14% -$157M 0.2% 110
2018
Q3
$1.25B Buy
16,159,381
+975,233
+6% +$73.7M 0.24% 87
2018
Q2
$1.08B Buy
15,184,148
+595,392
+4% +$42M 0.22% 95
2018
Q1
$1.1B Buy
14,588,756
+2,685,891
+23% +$214M 0.24% 85
2017
Q4
$853M Sell
11,902,865
-1,124,743
-9% -$85.4M 0.18% 121
2017
Q3
$1.05B Sell
13,027,608
-183,513
-1% -$14M 0.23% 86
2017
Q2
$935M Buy
13,211,121
+291,173
+2% +$19.4M 0.21% 93
2017
Q1
$878M Sell
12,919,948
-8,642,440
-40% -$608M 0.2% 102
2016
Q4
$1.55B Sell
21,562,388
-2,806,343
-12% -$209M 0.37% 46
2016
Q3
$1.93B Sell
24,368,731
-6,888,086
-22% -$560M 0.47% 31
2016
Q2
$2.61B Buy
31,256,817
+1,164,741
+4% +$103M 0.65% 20
2016
Q1
$2.76B Buy
30,092,076
+4,527,050
+18% +$408M 0.71% 16
2015
Q4
$2.59B Buy
25,565,026
+1,577,828
+7% +$164M 0.65% 18
2015
Q3
$2.36B Sell
23,987,198
-2,594,117
-10% -$288M 0.63% 21
2015
Q2
$3.11B Buy
26,581,315
+7,086,710
+36% +$774M 0.73% 13
2015
Q1
$1.91B Sell
19,494,605
-2,694,955
-12% -$274M 0.44% 40
2014
Q4
$2.09B Buy
22,189,560
+338,704
+2% +$35M 0.48% 30
2014
Q3
$2.33B Buy
21,850,856
+468,282
+2% +$45.9M 0.55% 27
2014
Q2
$1.77B Sell
21,382,574
-1,140,807
-5% -$88.8M 0.45% 35
2014
Q1
$1.6B Sell
22,523,381
-691,192
-3% -$54.2M 0.44% 40
2013
Q4
$1.74B Buy
23,214,573
+2,255,252
+11% +$157M 0.49% 34
2013
Q3
$1.32B Buy
20,959,321
+1,752,590
+9% +$105M 0.39% 46
2013
Q2
$985M Buy
+19,206,731
New +$1B 0.31% 64

Other funds holding GILD

JP Morgan Chase's GILD Position: Q2 2026 in Review

JP Morgan Chase reduced its Gilead Sciences (GILD) stake by 39% in Q2 2026, selling an estimated $1.74B and leaving 20,820,621 shares worth $2.63B. The position accounts for 0.15% of the portfolio, ranked #140.

JP Morgan Chase first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. The position peaked at $4.63B in Q1 2026. 2,261 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • JP Morgan Chase held 20,820,621 shares of Gilead Sciences worth $2.63B as of Q2 2026.
  • JP Morgan Chase sold 13,171,789 Gilead Sciences shares in Q2 2026, an estimated $1.74B.
  • Gilead Sciences made up 0.15% of JP Morgan Chase's portfolio in Q2 2026, its #140 holding.
  • JP Morgan Chase first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
  • JP Morgan Chase's Gilead Sciences position peaked at $4.63B in Q1 2026.
  • 2,261 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.